secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000950170-22-014798
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q2 2022 net loss $76.8M; pipeline progress, new board member
-------------------------------------------------------------------------------

- Net loss $76.8M ($0.71/share) in Q2 2022 vs $193.4M ($2.10) in Q2 2021; prior year included $134.9M ZebiAI acquisition costs.
- Cash $838M as of June 30, 2022, down from $958M at Dec 31, 2021; expected to fund operations into at least 2025.
- Appointed Sekar Kathiresan, CEO of Verve Therapeutics, to board of directors.
- FDA alignment on single-arm trial for RLY-4008 in FGFR2-fusion CCA; interim data showed 62% confirmed partial response (8/13) at 70 mg QD.
- Disclosed new breast cancer programs: selective CDK2 inhibitor, ERα degrader, and RLY-5836; RLY-2608 initial data expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022014798/0000950170-22-014798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022014798/rlay-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-014798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer